EXHIBIT 99.1
Pain Therapeutics Announces Second Quarter 2008 Financial Results
$30 Million Stock Buyback Completed
SAN MATEO, Calif., July 30, 2008 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the three and six months ended June 30, 2008. Net loss for the quarter ended June 30, 2008 was $1.0 million, or $0.02 per diluted share, compared to net income of $3.4 million, or $0.07 per diluted share, in the second quarter of 2007. Net income for the six months ended June 30, 2008 was $1.5 million, or $0.04 per diluted share, compared to $16.0 million, or $0.35 per diluted share, for the same period in 2007. Cash, cash equivalents and marketable securities were $177.1 million at June 30, 2008.
"In the first half of 2008, we made important progress to advance the profile of our drug candidates," said Remi Barbier, Pain Therapeutics' president and chief executive officer. "The NDA for Remoxy(tm), submitted in June, is a groundbreaking step towards the goal of launching the world's first abuse-resistant, long-acting formulation of oxycodone. In addition, we remain on-track with our goal of initiating the clinical development of another abuse-resistant opioid. Our confidence level for these abuse-resistant drug candidates, all partnered with King Pharmaceuticals, Inc., remains high."
"We also continue to advance our own proprietary drug candidates targeting important disease areas, and in June we announced promising early clinical results for a novel treatment for patients with advanced melanoma. These data were recently highlighted in two presentations at the annual scientific meeting of the Society for Nuclear Medicine, the world's most prestigious meeting focused on nuclear medicine."
"Our broad development investment is supported by a pristine balance sheet and tight fiscal discipline, enabling us to end the quarter with $177.1 million in cash and investments after the effects of completing a $30.0 million buyback of our stock," continued Remi Barbier.
Q2 2008 Financial Highlights
* In June 2008, we submitted to the U.S. Food and Drug
Administration (FDA) a New Drug Application (NDA) for Remoxy. We
believe the FDA will inform us if this NDA is accepted for
regulatory review by September. At such time we also expect to
learn if the NDA was granted priority review. Acceptance of the
Remoxy NDA by the FDA will trigger a $15.0 million cash milestone
payment from King Pharmaceuticals, Inc. (King), our commercial
partner for Remoxy.
* We met our goal to purchase $30.0 million of our stock in the open
market under a previously announced stock buyback plan.
* Collaboration revenue of $7.0 million and $18.0 million in the
three and six months ended June 30, 2008, respectively reflects
reimbursement of our development expenses under our strategic
alliance with King.
* Research and development expenses were $11.2 million and
$23.7 million in the three and six months ended June 30, 2008,
respectively. Most research and development expenses were
attributed to the development activities for our abuse-resistant
drug candidates, including expenses related to filing the NDA for
Remoxy. Research and development expenses included non-cash stock
related compensation costs of $1.0 million and $2.0 million in the
three and six months ended June 30, 2008, respectively.
* General and administrative expenses were $1.9 million and
$3.7 million in the three and six months ended June 30, 2008,
respectively. General and administrative expenses included
non-cash stock related compensation costs of $0.7 million and
$1.2 million in the three and six months ended June 30, 2008,
respectively.
2008 Financial Guidance - No Changes
* We continue to anticipate being cash flow positive in 2008.
* We anticipate receiving $20.0 million of cash milestone payments
in 2008 as follows:
-- $15.0 million cash milestone payment from King upon acceptance
of the NDA for Remoxy by the FDA.
-- $5.0 million cash milestone payment from King upon acceptance
of an Investigational New Drug (IND) application for a new
abuse-resistant opioid.
* We anticipate spending up to $15.0 million developing
biopharmaceutical products for metastatic melanoma, hemophilia and
other important disease areas. Pain Therapeutics holds all
commercial rights to these biopharmaceutical drug candidates.
About Pain Therapeutics, Inc.
Pain Therapeutics is a biopharmaceutical company that develops novel drugs. In June 2008, we submitted a NDA for Remoxy, an abuse-resistant form of long-acting oxycodone. We also have three drug candidates in clinical programs, including Oxytrex(tm), PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. In addition, we are working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates. For more information, please visit www.paintrials.com.
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the potential acceptance by the FDA of the Company's NDA for Remoxy and the potential acceptance by the FDA of an IND for a new abuse-resistant opioid; expected milestone payments from King in 2008; the Company's anticipation that it will be cash flow positive in 2008; and anticipated spending on biopharmaceutical development in 2008. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks an d uncertainties relating to difficulties or delays in development and testing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the uncertainty of patent protection for the Company's intellectual property or trade secrets, unanticipated research and development and other costs and the timing and receipt of funds from the Company's commercial partner. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.
PAIN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
------------------ ------------------
2008 2007 2008 2007
-------- -------- -------- --------
Revenue
Collaboration revenue $ 6,960 $ 7,515 $ 18,013 $ 23,018
Program fee revenue 3,587 6,550 7,173 13,100
-------- -------- -------- --------
Total revenue 10,547 14,065 25,186 36,118
Operating expenses
Research and development 11,215 11,044 23,699 20,903
General and administrative 1,896 2,102 3,716 3,940
-------- -------- -------- --------
Total operating expenses 13,111 13,146 27,415 24,843
-------- -------- -------- --------
Operating income (loss) (2,564) 919 (2,229) 11,275
Interest income 1,539 2,446 3,774 4,726
-------- -------- -------- --------
Net income (loss) $ (1,025) $ 3,365 $ 1,545 $ 16,001
======== ======== ======== ========
Net income (loss) per share
Basic $ (0.02) $ 0.08 $ 0.04 $ 0.36
======== ======== ======== ========
Diluted $ (0.02) $ 0.07 $ 0.04 $ 0.35
======== ======== ======== ========
Weighted-average shares used
in computing net income (loss)
per share
Basic 41,579 44,025 42,714 44,183
======== ======== ======== ========
Diluted 41,579 45,180 43,974 45,303
-------- -------- -------- --------
PAIN THERAPEUTICS, INC
CONDENSED BALANCE SHEETS
June 30, December 31,
2008 2007(1)
----------- -----------
(Unaudited)
Assets
Current assets
Cash, cash equivalents and marketable
securities $ 177,073 $ 205,071
Other current assets 32 303
----------- -----------
Total current assets 177,105 205,374
Non-current assets
Property and equipment, net 1,373 1,607
Other assets 644 644
----------- -----------
Total assets $ 179,122 $ 207,625
=========== ===========
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 3,206 $ 3,624
Accrued development expense 822 817
Deferred program fee revenue - current
portion 14,348 14,348
Other accrued liabilities 1,478 1,868
----------- -----------
Total current liabilities 19,854 20,657
Non-current liabilities
Deferred program fee revenue - non-current
portion 75,328 82,501
Other liabilities 553 553
----------- -----------
Total liabilities 95,735 103,711
----------- -----------
Stockholders' equity
Common stock 41 44
Additional paid-in-capital 210,785 221,415
Accumulated other comprehensive income 465 584
Accumulated deficit (127,904) (118,129)
----------- -----------
Total stockholders' equity 83,387 103,914
----------- -----------
Total liabilities and stockholders' equity $ 179,122 $ 207,625
=========== ===========
(1) Derived from audited financial statements
CONTACT: Pain Therapeutics, Inc.
Christi Waarich, Senior Manager of Investor Relations
650-645-1924
cwaarich@paintrials.com
